Friday, April 19, 2013

Central Nervous System (CNS) Biomarkers

In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts and leading individuals in the field.The CNS biomarker and drug markets comprise drug products for treatment of a number of specific diseases afflicting both men and women. For completeness, the current and forecasted markets comprise the total market opportunity for each respective segment.Information to prepare this report was obtained from participating and emerging companies in the biomarker and CNS drug areas and from the following institutes within the National Institutes of Health (NIH): National Institute of Mental Health (NIMH), the National Institute of Aging (NIA), the National Institute of Neurological Diseases and Stroke (NINDS), National Human Genomic Research Institute (NHGRI), the NIH’s Center of Information Technology (CIT) and the National Library of Medicine (NLM).Additional information was obtained from a variety of medical and technical journals on the various specialties within biomarker and CNS applications. Other sources included the New York Times, Wall Street Journal, Washington Post, other newspapers, company documents and Internet websites. Population estimates are based on those reported by the International Data Base of the U.S. Census Bureau. Statistical data was obtained from the World Health Organization (WHO) and the Collaborating Centre for Drug Statistics Methodology (Norway).
To Know More -Central Nervous System (CNS) Biomarkers

1 comment:

  1. The global central nervous system (CNS) biomarker market was valued at nearly $2 billion in 2012. The market is projected to reach nearly $5.1 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 20.7%.

    central nervous system biomarkers